Internal Medicine, Hematology & Oncology · New York, NY
NPI
1063537041
Since 2007
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
0
Hospital affiliations
139 Centre St, Suite 515
New York, NY, 10013
Phone (212) 941-9020
Groups this clinician bills Medicare through
Medicare paid, 2024
$79K
7,627 services
Medicare patients, 2024
121
Average age 76
Drug cost, 2024
$20.4M
5,078 prescriptions
Company payments, 2025
$46K
From 61 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Norland Ng was code 99214 (office e&m - established), 254 times for 88 patients. In total Norland Ng billed 7,627 services in 65 codes, and Medicare paid $79K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2017-03-30.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 254 | 88 | $104.51 | $27K |
| 36415 Venipuncture Blood Collection | Office | 122 | 63 | $8.65 | $1,055 |
| 96127 Behavioral Health Services | Office | 88 | 44 | $3.16 | $278 |
| 99497 Care Management/Coordination | Office | 54 | 51 | $66.83 | $3,609 |
| 99213 Office E&M - Established | Office | 43 | 28 | $65.77 | $2,828 |
| J7050 Infusion, normal saline solution, 250 cc | Office | 40 | 11 | $0.51 | $20.27 |
| 85025 Blood Count | Office | 35 | 18 | $7.61 | $266 |
| G0444 Annual depression screening, 5 to 15 minutes | Office | 26 | 26 | $21.12 | $549 |
| 99204 Office E&M - New | Office | 16 | 16 | $135.95 | $2,175 |
By year: 2022 $105K for 15,100 services; 2023 $139K for 16,577 services; 2024 $79K for 7,627 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 122 | 63 | $8.65 | $1,055 |
| 85025 Blood Count | 35 | 18 | $7.61 | $266 |
Medicare prescription drug claims, 2024
In 2024, the drug Norland Ng prescribed most often to Medicare patients was Anastrozole, with 269 prescriptions and refills. In total Norland Ng wrote 5,078 Medicare prescriptions that cost $20.4M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Anastrozole Generic | 269 | 613 | 67 | $3,413 |
| Orgovyx Relugolix | 182 | 182 | 22 | $490K |
| Tagrisso Osimertinib Mesylate | 172 | 172 | 19 | $3.0M |
| Tamoxifen Citrate Generic | 124 | 293 | 35 | $3,893 |
| Rosuvastatin Calcium Generic | 114 | 330 | 46 | $1,456 |
| Hydroxyurea Generic | 109 | 227 | 25 | $2,720 |
| Losartan Potassium Generic | 95 | 245 | 35 | $924 |
| Abiraterone Acetate Generic | 94 | 102 | Under 11 | $92K |
| Prednisone Generic | 87 | 161 | 27 | $772 |
| Levothyroxine Sodium Generic | 81 | 223 | 27 | $887 |
| Jakafi Ruxolitinib Phosphate | 81 | 81 | Under 11 | $1.4M |
| Atorvastatin Calcium Generic | 78 | 170 | 28 | $701 |
| Dexamethasone Generic | 77 | 83 | 29 | $1,270 |
| Reblozyl Luspatercept-Aamt | 77 | 77 | Under 11 | $915K |
| Ammonium Lactate Generic | 77 | 77 | 27 | $2,121 |
Brand drugs: 1,819 claims; generic drugs: 3,230 claims; opioid claims: 68.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Norland Ng $46K ($46K in general payments such as food, travel and fees) from 61 companies. The largest payer was Agios Pharmaceuticals, Inc. with $23K.
| Company | Payments | Amount |
|---|---|---|
| Agios Pharmaceuticals, Inc. AGIO | 34 | $23K |
| AstraZeneca Pharmaceuticals LP AZN | 26 | $4,031 |
| EMD Serono, Inc. MRK.DE | 4 | $2,532 |
| Pfizer Inc. PFE | 28 | $2,147 |
| Incyte Corporation INCY | 12 | $1,581 |
| Recordati_rare_diseases_inc. | 5 | $1,412 |
| Janssen Scientific Affairs, LLC JNJ | 2 | $1,117 |
| Janssen Biotech, Inc. JNJ | 34 | $1,006 |
| Daiichi Sankyo Inc. 4568.T | 18 | $923 |
| Novartis Pharmaceuticals Corporation NVS | 21 | $581 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.